These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 34569489)
21. Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. Sinha SD; Bandi VK; Bheemareddy BR; Thakur P; Chary S; Mehta K; Pinnamareddy VR; Pandey R; Sreepada S; Durugkar S BMC Nephrol; 2019 Mar; 20(1):90. PubMed ID: 30866856 [TBL] [Abstract][Full Text] [Related]
22. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis. Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498 [TBL] [Abstract][Full Text] [Related]
23. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887 [TBL] [Abstract][Full Text] [Related]
24. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents. Silver MR; Geronemus R; Krause M; Chen CY; Kewalramani R; Stehman-Breen C Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145 [TBL] [Abstract][Full Text] [Related]
25. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926 [TBL] [Abstract][Full Text] [Related]
26. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
27. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857 [TBL] [Abstract][Full Text] [Related]
31. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials. Krause MW; Raja R; Agarwal A; Silver MR; Scarlata D; Sciarra A; Kewalramani R Drugs Aging; 2009; 26(8):665-75. PubMed ID: 19685932 [TBL] [Abstract][Full Text] [Related]
32. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. Akizawa T; Ueno M; Shiga T; Reusch M Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449 [TBL] [Abstract][Full Text] [Related]
33. Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India. Mazahir R; Anand K; Pruthi PK Eur J Pediatr; 2023 Jan; 182(1):101-109. PubMed ID: 36220980 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis. Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478 [TBL] [Abstract][Full Text] [Related]
35. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
36. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989 [TBL] [Abstract][Full Text] [Related]
37. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537 [TBL] [Abstract][Full Text] [Related]
39. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415 [TBL] [Abstract][Full Text] [Related]
40. Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease. Al Raisi F; Al Salmi I; Kamble P; Al Shehri M; Shaheen FA Saudi J Kidney Dis Transpl; 2016; 27(6):1182-1187. PubMed ID: 27900963 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]